202002.21
0

DEG’s support of Finnegan and their client Biogen help win sweeping victory against Mylan over patent dispute regarding best-selling multiple sclerosis drug, Tecfidera

in News

The Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO) gave a favorable ruling to Biogen who holds a market exclusivity in the United States until 2028 on their ’514 patent covering the treatment for multiple sclerosis with 480mg dose of dimethyl fumarate. Tecfidera represents 39% of the company’s total…

202002.07
0

With the assistance of DEG, Sterne Kessler wins favorable ITC ruling for vaping pioneer, JUUL Labs, Inc.

in News

DEG supported Sterne Kessler and their client, vaping giant, JUUL Labs Inc. in Certain Electronic Nicotine Delivery Systems and Components Thereof, investigation number 337-TA-1139, before the U.S. International Trade Commission. The commission partly affirmed Judge David P. Shaw’s initial determination that Eonsmoke LLC infringed patents for Juul’s electronic nicotine delivery systems. In his November determination,…

201909.21
0

DEG works alongside Finnegan’s stellar trial team who secures patent protection for Relistor Tablets until March 2031

in News

The U.S. District Court of New Jersey upheld the validity of Bausch Health Companies Inc.’s patent protecting Relistor (methylnaltrexone bromide) tablets and determined Actavis’ infringement of the patent for opioid-induced constipation in patients with chronic non-cancer pain. The case is Bausch Health Cos. Inc. et al., v. Actavis Laboratories FL Inc., case number 16-cv-9038, in…

201904.22
0

DEG helps Sterne Kessler on their ITC victory for German client and road milling machine company, Wirtgen

in News

DEG assisted Sterne Kessler on their 337-TA-1067 win before the U.S. International Trade Commission for their client Wirtgen providing depositions, videographers, 2D/3D graphics and hot seat support. Sterne Kessler secured a victory at the ITC striking down Caterpillar Inc.’s effort to invalidate one of the patents held by the German company. In 2017, Wirtgen accused…

201904.09
0

A huge victory for Finnegan Henderson on their PTAB win on behalf of Incyte Corp. in hair loss treatment patent challenge

in News

DEG worked closely with Finnegan Henderson on this matter and in a final inter partes review decision the Patent Trial and Appeal Board granted Incyte Corp. a victory by ruling Concept Pharmaceuticals Inc.’s patent relating to a potential hair loss treatment was unpatentable. Concert owns a patent with claims covering CTP-543 – a chemical compound…

201812.21
0

DEG congratulates the Faeger Drinker Biddle & Reath IP litigation team for their significant win at the ITC on behalf of client GC Corporation and GC America

in News

DEG is proud to have worked with Faeger Drinker (formerly Drinker Biddle) as they defended their long-time client and leader in the global oral health industry against allegations of patent infringement brought by Ivoclar Vivadent AG and other affiliates. In Certain Dental Ceramics, Products Thereof, and Methods of Making the Same, Inv. No. 337-TA-1050, the…

201702.03
0

DEG is proud to have supported Finnegan and it’s client AstraZeneca in their trial win covering its $3.5 billion diabetes drug patent

in News

On February 3, 2017, Judge Gregory M. Sleet found in favor of AstraZeneca’s patents covering its diabetes drugs Onglyza and Kombiglyze. U.S. District Judge of Delaware ruled that five generic makers failed to show that two asserted claims of AstraZeneca AB’s U.S. Patent Number RE44,196 are invalid as obvious in light of prior art, saying…